WATCH: China patent landscape

Jennifer Che, President and Managing Director at Eagle IP, provides a comprehensive update on the top patent issues life sciences companies are currently facing in China.The presentation highlights major legal conclusions, including the final word on post-filing data following the resolution of the Semaglutide case at the highest court. It also breaks down recent developments surrounding data exclusivity, patent linkage, patent term extensions (PTE), and safe harbour provisions.In addition to covering these legislative shifts, the session offers a forward-looking perspective on how emerging technologies, such as AI, are being addressed within the Chinese patent system, equipping practitioners to adapt to forthcoming regulatory changes.